Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antisense
Biotech
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Alnylam and Biogen published early-phase data on their respective RNAi and antisense approaches to treating the neurodegenerative disease.
Nick Paul Taylor
Oct 26, 2023 8:51am
Takeda snaps $580M for shot at ALS pick 6 with AcuraStem
Sep 26, 2023 9:15am
Ionis' lipid-lowering drug hits phase 3 goal, teeing up filings
Sep 26, 2023 7:00am
Roche drops antisense drug after seeing early efficacy data
Jun 23, 2023 5:00am
Ionis' midphase misses send rare disease prospects to the abyss
May 4, 2023 10:25am
Biogen gets mixed decision at FDA AdComm on failed ALS drug
Mar 23, 2023 6:45am